Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a significant revenue increase and extended cash runway, which are positive. However, the dependency on partnerships for advancing the norovirus program and the BARDA stop work order pose risks. The Q&A session revealed uncertainty about independent trial initiation for the norovirus program, reflecting potential challenges. These mixed signals suggest a neutral sentiment, with positive financials balanced by strategic uncertainties.
Key Financial Performance
Revenue for Q3 2025 $72.4 million compared to $4.9 million for Q3 2024, representing a significant increase. The increase was primarily due to the BARDA contract awarded in June 2024.
Cash, cash equivalents, and investments $28.8 million at the end of Q3 2025. The cash runway is extended into Q2 2027 due to proceeds from the license agreement with Dynavax received after the quarter close.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Oral COVID-19 Vaccine: Vaxart announced a partnership with Dynavax, potentially worth up to $700 million in license, regulatory, and milestone fees, plus royalties. Dynavax will pay an upfront license fee of $25 million and make a $5 million equity investment. Vaxart retains responsibility for the ongoing Phase IIb trial, with Dynavax potentially paying an additional $50 million post-trial. Future regulatory and sales milestones could bring up to $620 million.
Norovirus Vaccine: Positive Phase I results for second-generation constructs showed stronger antibody responses compared to first-generation constructs. The program is ready for the next clinical trial, pending funding or partnership, with a potential start in 2026.
Partnership with Dynavax: The collaboration with Dynavax enhances Vaxart's market positioning by validating its oral vaccine platform and providing resources for late-stage development. Dynavax gains exclusive worldwide rights to develop and commercialize oral COVID-19 vaccines.
Cash Runway Extension: The Dynavax agreement extends Vaxart's cash runway into Q2 2027, supported by upfront payments and equity investment.
BARDA Funding Continuation: BARDA continues to fund follow-up for the Phase IIb COVID-19 trial, covering approximately 5,400 enrolled subjects.
Focus on Oral Vaccine Platform: Vaxart emphasizes its oral vaccine platform's potential to transform global public health and revolutionize vaccine distribution and administration.
Partnership Development: Vaxart is actively seeking partnerships for its norovirus, flu, and HPV programs to secure funding and advance clinical trials.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
BARDA Stop Work Order: The Phase IIb clinical study for the COVID-19 oral pill vaccine faced a stop work order from BARDA, halting enrollment and potentially delaying progress. This could impact the timeline and funding for the program.
Funding Dependency for Norovirus Program: The advancement of the norovirus vaccine program is contingent on securing partnerships or additional funding, delaying the next clinical trial to 2026. This dependency poses a risk to the program's progress.
Regulatory and Clinical Development Uncertainty: The success of the COVID-19 and norovirus programs depends on regulatory approvals and clinical trial outcomes, which are inherently uncertain and could adversely impact the company's strategic objectives.
Economic Cost of Norovirus: While the economic burden of norovirus is significant, the lack of an approved vaccine and competition in the vaccine space could challenge Vaxart's ability to capitalize on this opportunity.
Cash Runway Limitations: Despite extending the cash runway into Q2 2027, the company remains reliant on strategic partnerships and nondilutive funding to sustain operations and advance its pipeline.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
COVID-19 Oral Vaccine Program: Vaxart has entered into a partnership with Dynavax, which could provide up to $700 million in license, regulatory, and milestone fees, along with royalties. The company will retain responsibility for the program through the Phase IIb clinical trial and expects to announce multiple datasets in 2026. Dynavax may assume responsibility for further development after Phase IIb, potentially providing additional payments and royalties. The program aims to address the ongoing prevalence of COVID-19 and advance global public health.
Norovirus Vaccine Program: Vaxart plans to initiate the next clinical trial for its second-generation norovirus vaccine in 2026, pending funding or partnership agreements. The vaccine has shown promising Phase I results, with significantly stronger antibody responses compared to the first-generation constructs. The company is actively seeking partnerships to advance this program.
Financial Guidance: With the Dynavax agreement and current cash reserves, Vaxart's cash runway extends into the second quarter of 2027. The company is pursuing additional strategic partnerships and funding options to further extend its financial runway.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why did Dynavax decide to reach a deal now instead of waiting for data from the sentinel cohort in early 2026?
A:Dynavax decided to proceed with the deal now due to the strong fit between the companies and the potential of the platform, including oral delivery and mucosal immunity. They conducted thorough due diligence and felt comfortable moving forward despite being blinded to the clinical data.
Q:What data did Dynavax see before reaching the deal?
A:Dynavax conducted due diligence on the platform and its potential. However, both companies are blinded to the clinical trial data, which will only be available in Q1 2026 for the sentinel cohort and Q4 2026 for the larger KP.2 cohort.
Q:With the additional funding from Dynavax, can the company start the Phase IIb trial for the norovirus program by itself?
A:The company is exploring opportunities for partnerships for its assets, including norovirus, HPV, and flu. The additional funding validates the platform and has sparked interest in potential collaborations, but the company remains committed to its current pipeline.
Q:How does the company view this year's COVID season compared to last year, and what is the market potential for an oral COVID vaccine?
A:The company sees a sizable market for COVID vaccines despite reduced uptake due to perceived side effects, hassle, or media coverage. An oral vaccine offers advantages like convenience and differentiation. The company has demonstrated manufacturing versatility for different strains.
Q:How does the product respond to strain changes in COVID and norovirus?
A:The product has shown cross-reactivity to multiple strains and the ability to adapt to strain changes. The ongoing study will evaluate efficacy over 12 months, including strain analysis. The mucosal response may reduce virus transmission, offering additional health benefits.
Q:Review of Unclear Management Responses
A:Management avoided directly answering whether the company could independently start the Phase IIb trial for the norovirus program. They emphasized ongoing partnership discussions and the validation of their platform but did not provide a clear plan or timeline for initiating the trial independently.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
COVID pill
COVID program
COVID vaccine
GI IgA
GII IgA
IIb trial
IgA response
Jeroen
Phase II
Phase IIb
Principal
administration strain
agreement cash
agreement license
baseline dose
candidate tablet
collaboration
development asset
dose generation
fee
follow subject
increase GI
increase GII
increase generation
license agreement
milestone payment
month line
potential protection
response baseline
response generation
response increase
responsibility development
tablet administration
track
vaccine delivery
vaccine program
view
VXRT Transcript
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call highlights a significant revenue increase and extended cash runway, which are positive. However, the dependency on partnerships for advancing the norovirus program and the BARDA stop work order pose risks. The Q&A session revealed uncertainty about independent trial initiation for the norovirus program, reflecting potential challenges. These mixed signals suggest a neutral sentiment, with positive financials balanced by strategic uncertainties.
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed outlook. Positive aspects include revenue growth, a strong cash runway, and promising vaccine developments. However, workforce reductions, dependency on external funding for trials, and uncertainties in partnerships and trial progress are concerning. The Q&A highlighted management's lack of clarity on key issues, such as the COVID-19 trial's stop work order, which raises uncertainty. Despite potential catalysts like the avian flu vaccine, uncertainties and financial challenges balance out the positives, leading to a neutral sentiment.
Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call summary presents mixed signals: strong revenue growth and positive discussions with BARDA and potential partners are countered by regulatory and operational risks, including NASDAQ compliance concerns and workforce reductions. The Q&A reveals management's cautious optimism but also highlights uncertainties, especially regarding timelines and specifics on the COVID program. These factors, along with a potential reverse stock split, suggest a neutral short-term stock price movement, with no clear catalyst for significant gains or losses.
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript
Unknown3-24
The earnings call highlights significant challenges, including a stop work order from BARDA and workforce reductions, indicating financial and operational strain. Despite a positive EPS surprise, the lack of clear guidance on future product efficacy and management's vague responses during the Q&A add to uncertainties. The increase in revenue is overshadowed by these issues, and future funding strategies are speculative. The overall sentiment leans negative due to regulatory and competitive pressures, potential supply chain issues, and the need for strategic funding to maintain operations.
VXRT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
